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Aminoglycosides have long been used for their broad-spectrum activity against 
gram-positive and gram-negative bacteria. However, the continuous incidence of 
bacterial resistance has forced researchers to explore additional applications, including 
potential treatments for genetic neural disorders, diseases associated with mutations of 
gap junction proteins, and fungal infection. For these novel applications of 
aminoglycosides, chemical modification of naturally occurring aminoglycosides is often 
necessary. One such modified aminoglycoside, TC007, has been identified as a potent 
lead in the treatment of spinal muscular atrophy (SMA). Even though our previous lab 
members had already synthesized TC007, there has been a high demand for this 
compound for testing against SMA and characterizing its molecular interactions in the 
cell. However, de novo synthesis of 3- and 6-aminosugars and their corresponding 
glycosyl donors can be time- and resource-consuming and challenging to master.  For 
example, the synthesis of the 3-aminoglucopyransyl donor, essential for the synthesis of 
this compound, involves a metal-based reagent and is challenging as it requires more than 
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ten synthetic steps with a meager overall yield. An alternative approach is to utilize 
natural products containing 3-and 6-aminopyranose. Many naturally occurring or 
synthetic bioactive compounds contain 3-and 6-aminoglucopyranosyl moieties. The 
reported acid-catalyzed hydrolysis of azidokanamycin A offered an alternative route to 
the synthesis of these molecules. The 3-and 6 aminosugar donor was synthesized in just 
two steps; however, the yield was very poor. An excellent yield was achieved with the 
hydrolysis of azidokanamycin B, but the cost of starting material was very high. 
Nevertheless, the synthesis of donors from carboxy benzyl (Cbz or Z) protected 
kanamycin A (Z4K) was found to be the best route with excellent yield, short synthetic 
steps, and it was very cost-effective. The acidic hydrolysis of these aminoglycosides not 
only provided the 3- and 6-aminosugars but also proved the direct chemical glycosylation 
of these aminosugars was feasible using isopropanol and octanol as the acceptor. 
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The synthesis of 3- and 6- aminosugars from the old route requires many synthetic 
steps and is challenging. An alternative approach is to utilize acid-catalyzed hydrolysis of 
kanamycin derivatives. The 3-and 6 aminosugar donor was synthesized in just two steps 
with excellent yield and cost-effective. The acidic hydrolysis of these aminoglycosides 
provided not only the 3- and 6-aminosugars, but the direct chemical glycosylation of these 
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 The discovery of kanamycin in 1957 by Hamao Umezawa 1 was a breakthrough 
in the area of antibiotics due to its antibacterial activity.2   Kanamycin belongs to a group 
of chemicals known as aminoglycosides (AGs). AGs are broad-spectrum antibiotics that 
have been in use for over 70 years.3-4 Structurally, these compounds are made up of one 
or more amino saccharides and a 2-deoxystreptamine connected through a glycosidic 
linkage. AGs are classified based on the substitution position of 2-deoxystreptamine. The 
neomycin class of AGs contains a 4,5 disubstituted 2-deoxystreptamine, kanamycins 
contain a 4,6-disubstituted 2-deoxystreptamine, and a third-class includes a 
monosubstituted 2-deoxystreptamine, e.g., streptomycin (figure 1-1).
Despite the potential for renal toxicity and ototoxicity, kanamycin and other AGs 
remained essential for the treatment of infectious diseases for several decades.5 However, 
years of continual usage have caused bacteria to develop resistance which has 
compromised the clinical use of AGs.6-7 
1-2 Repurposing the application of aminoglycosides
Reviving the antibacterial activity of AGs and searching for different applications 
has been the primary focus for many researchers around the globe.8-9 Beyond the 
traditional antibacterial uses, potential applications of aminoglycosides include 
treatments for genetic disorders,10 diseases associated with mutations of gap junction 
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proteins,11-12 and fungal infections.13-15 For these novel applications of aminoglycosides, 















1-3 Aminoglycosides in the treatment of genetic disorders 
The critical interaction of drugs with nucleotides of the ribosomal RNA (rRNA) 
are different in bacteria and humans.16 The selective binding of AGs to the bacterial 
ribosome results in the antibacterial activity. The  A1408 and G1491 of the bacterial 
ribosome small subunit decoding site likely determines the selectivity of 
aminoglycosides.17-18 The guanine residue at position 1408 and an adenine residue at 
position 1491 in eukaryotic 18S rRNA reduces interaction with aminoglycosides, though 
conserved nucleotides suggest the binding of certain aminoglycosides to the small 
subunit of both bacterial and eukaryotic ribosomes.10 This finding was a turning point to 
the utilization of AGs in the treatment of genetic diseases, especially those due to 
nonsense mutations. Nonsense mutations result from a change in a single nucleotide in a 
DNA sequence that converts the codon of an amino acid into a termination codon.19 The 
consequence of a nonsense mutation is the premature termination of protein translation, 
causing the production of non-functional proteins.20-21 Burke and Mogg22 demonstrated 
that aminoglycosides could suppress the effect of a nonsense mutation by binding to the 
decoding site. The impact of this binding is the reduction of the translational fidelity by 
AG, allowing a random amino acid to incorporate at a premature termination codon in 
mammalian cells. Hence, the protein translation proceeds through to the natural stop 
codon.23 This concept introduced a broad area of novel research in the field of 
aminoglycosides as a stop codon read-through inducer and as a therapeutic agent for 







1-4 Spinal Muscular Atrophy 
 
Abnormalities caused by a defect in an individual’s genome are genetic disorders. 
These disorders are inheritable or could result from a mutation in the DNA. 24 Spinal 
muscular atrophy (SMA) is a neurodegenerative disorder caused by the homozygous loss 
of the Survival Motor Neuron 1 (SMN1) gene.25 It is a leading cause of infant mortality 
from genetic disorders and affects one in every 8,000 – 10,000 births worldwide.26-27  
SMA is characterized by the death of motor neurons present in the anterior horn of the 
spinal cord.28-29 It causes muscle weakness and wasting of skeletal muscles.30 There are 
five types of SMA based on disease severity and the age of onset.31 SMA type 0 is the 
rarest, yet the most severe form of SMA, and it manifests itself before childbirth. It can 
be fatal inside the womb and mostly fatal during the early months after birth. Type I 
SMA is the most common and severe form that occurs in the first months of life (0-6 
months), while Type II is an intermediate form that manifests between 6 and 18 months 
of life. Type III shows after 18 months, whereas Type IV SMA appears after 35 years of 
age. Numerous research has been carried out over the past several decades to develop 
new and improved drugs to treat SMA. Several drugs are in the clinical trial, and a couple 
were approved by the Food and Drug Administration (FDA) in 2017.32-33 
Through collaboration with Dr. Christian Lorson and co-workers (Department of 
Veterinary Pathobiology, Bond Life Sciences Center, University of Missouri), our 
libraries of previously synthesized aminoglycosides were screened to identify the 
modified AG TC007 34 (figure 1-2) as the lead in the treatment of SMA. 35 
The interaction of TC007 with the eukaryotic ribosome is not fully explored yet. 
However, recent studies revealed the specific binding of TC007 in the decoding site of 
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the eukaryotic ribosome which triggers the insertion of an amino acid such as tyrosine in 
the premature stop codon. This binding is so specific that it only affects the mutant stop 
codon and not the natural stop codon. This process allows the ribosome to read- through 
until it finds a natural stop codon. Hence, TC007 became a potential candidate to be used 
as a therapeutic agent against SMA. 35-36 
TC007 is produced using a glycosylation strategy,34 not a direct modification 
strategy.37 The direct-modification approach commonly employs a naturally occurring 
aminoglycoside as the starting material and provides a cost-effective synthesis of desired 
products, albeit lacking flexibility in structural variation.38 The glycosylation strategy 
allows more structural flexibility but requires the synthesis of designed glycosyl donors, 
which can be both time- and resource-consuming.39-40 Therefore, my goal was to prepare 
more TC007 by synthesizing the glycosyl donor through an alternative route.  
1-5 3-and 6-aminosugars 
The incorporation of amino sugars in different chemical entities has been 
prevalent in drug design for decades. 41 3-aminoglucopyranose and 6-
aminoglucopyranose has received significant attention due to their considerable 
biological and pharmacological importance. Aminosugars, such as 3- and 6-aminosugars, 
are prevalent in diverse naturally occurring as well as synthetic bioactive compounds.42-43 
For example, antibacterial erythromycin and azithromycin, anticancer daunorubicin, and 
antifungal amphotericin B contain 3-aminosugar (figure 1-2). A 3-aminosugar is also 
present in the synthetic AG TC007, and the 6-aminosugars are present in antiviral 
glycolipid derivatives.44 Also, workers often employ a glycodiversification approach to 
incorporate various aminosugars to reveal useful structure-activity relationships of 
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bioactive glycosides.45-46 All these points to the essential need to prepare aminosugar-
based glycosyl donors. 
Most of the reported chemical synthesis of glycosyl donors carrying 3- and 6-
aminosugar scaffolds start with cost-effective glucose.39 However, the overall 
transformation can be labor-intensive, which involves many protections and deprotection 
steps, stereoselective and regioselective modifications of hydroxyl groups, and amino 
group manipulation. For example, regioselective conversion of the 6-OH of glucose to 6-
NH2 takes 4-6 synthetic steps, depending on the starting material (scheme 1-1).
47 The 
stereoselective synthesis of 3-aminosugar usually starts with commercially available 
glucose. Six synthetic steps and at least 2-3 column chromatography purifications are 
needed to produce the precursor of the glycosyl donor, 9, making the overall process hard 
to master.48  Also, several reported syntheses employ hazardous chromium-based 
oxidants.49-50 Therefore,  an alternative route is sought for the synthesis of  3-and 6-
aminoglucopyransyl donors. 
 








Figure 1-2. Bioactive compounds bearing 3- and 6-aminosugars 
1-6 Synthesis of TC007 via old route 
The synthesis of TC007 through the old route followed the protocol, as described 
by Dr. Ravi Rai. 51 The synthesis of the acceptor started from the commercially available 
neomycin B. The amino groups were converted into azido groups and then benzylated to 
produce compound 2 52 (scheme 1-2). The glycosidic bond between rings II and III was 
cleaved by refluxing 3 in the presence of copper (II) chloride, and this gave the known 
neamine derivative 4, the glycosyl acceptor. 52  
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The synthesis of the 3- amino sugar donor precursor 9 started from the 
commercially available glucose 5. Swern oxidation of the diacetone-D-glucose and 
reduction of the corresponding ketone with NaBH4 gave the epimer alcohol 7. 
53 Triflation, 
SN2 azido substitution, and acid-catalyzed hydrolysis resulted in 3-azido sugar 9 (scheme 
1-3).  The acetylation of 3- azido sugar 9, provided the tetraacetyl pyranose 10. 54 Treatment 
with hydrazine acetate selectively hydrolyzed the acetyl group at the anomeric position to 
give 11, 55 whose free hydroxyl group was then activated in the presence of 
trichloroacetonitrile to afford the glycosyl donor 12 (scheme 1-4). 35 
  Glycosylation of acceptor 4 and donor 12 in the presence of the Lewis acid BF3-
OEt2 provided compound 16 (scheme 1-5). 
35 BF3-OEt2 activated the donor 12 and formed 
an oxocarbenium intermediate, which in the presence of a 2-O-acyl group gave an 
acyloxonium intermediate. Thus, the attack by an acceptor (a nucleophile) was only 
possible from the open-top face, controlling the stereochemistry in the formation of the β-
anomer. The deacetylation using sodium methoxide in methanol, Staudinger reduction of 































Scheme 1-4. Synthesis of Glycosyl donor by old route 
 
 







1-7 Hydrolysis of Aminoglycosides 
Leach and Teeters 56  were pioneers in the hydrolysis of neomycin. Cron et al.57 
studied the hydrolysis of kanamycin and the antimicrobial activity of its hydrolyzed 
products. The hydrolysis of tobramycin to synthesize more active antibiotics also 
increased the importance of research in the field of aminoglycoside hydrolysis.58 
Naturally occurring aminoglycosides, such as the kanamycin class of antibiotic, 
consist of various aminosugars that are linked together via glycosidic bonds (figure 1-
1).53-55 Thus, an alternative approach for the synthesis of glycosyl donors of 3- and 6-
aminosugars is to conduct acid-catalyzed hydrolysis of aminoglycosides and recover the 
desired aminosugars.  
Acid-catalyzed hydrolysis of kanamycin offers two aminosugars (rings I and III), 
which are difficult to separate.  The separation gets more difficult due to the fact that the 
aminosugars occur as a mixture of anomers.35, 51 The reported methods also commonly 
use hydrochloric and sulfuric acids which cause the formation of viscous, brownish by-
products. This makes purification of the desired products even more challenging. 
Nevertheless, very little work has been reported on the use of hydrolysis of 
aminoglycosides to synthesize different amino sugars, and a detailed study of breaking 
the glycosidic bond is still in progress.  
Herein, we develop an alternative approach involving the hydrolysis of 
azidokanamycin, and cbz-kanamycin for obtaining the precursor of glycosyl donors in 
fewer synthesis steps, increasing the yield and making it safer and more economical. We 
will also demonstrate the feasibility of one-pot glycosylation during the acid-catalyzed 




MATERIALS AND METHODS 
 
2-1 Experimental Reagents and Instruments  
All chemicals were purchased through commercially available sources without 
any further purification. Mass was measured by high-resolution mass spectrometry 
(HRMS). Bruker Ascend (500 MHz) NMR instrument was used for the 1H and 13C 
nuclei. CDCl3, CD3OD, and DMSO-d6 were used as solvents. Parts per million (ppm) 
were used to express the chemical shifts on d scale. The peaks splitting pattern were 
expressed as (s: for the singlet), (d: doublet), (t: triplet), (q: quadrate), (m: multiplet), and 
(ddd: doublet of doublets of doublets). Coupling constants J were measured in Hertz 
(Hz).  
2-2 Experimental Procedures 
2-2 .1 General procedure for the hydrolysis of azido-compounds 
 
Method 1:  
Hydrolysis of tetraazidokanamycin A 
To 25 mL of methanol cooled to 0 °C, 8.33 mL of acetyl chloride (excess) was 
added dropwise, keeping the flask in the ice bath and stirred for 5 minutes. Then 0.5g of 
tetraazidokanamycin A 59 (0.85mmol, 1 equivalent) was added to the reaction mixture. 
After 48 hours of the reaction at room temperature, the formation of the product was 
confirmed by TLC (Dichloromethane (DCM): Methanol = 90:10, Retention Factor (Rf) = 
0.4 to 0.8). The crude reaction mixture after concentrated under reduced pressure and 
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loaded to a silica gel column. The column was eluted using DCM and methanol solvent 
mixture with the proportion from (100:0) to (95:5) to afford 18-20. 
Hydrolysis of pentaazidokanamycin B  
To 25 mL of methanol cooled to 0 °C, 8.33 mL of acetyl chloride (excess) was 
added dropwise, keeping the flask in the ice bath and stirred for 5 minutes. Then, 0.5 g of 
pentaazdiokanamycin B 59 (0.81mmol, 1 equivalent) was added to the reaction mixture. 
After 48 hours of the reaction at room temperature, the formation of the product was 
confirmed by TLC (DCM: Methanol = 90:10, Rf = 0.6 to 0.8). The crude reaction mixture 
was concentrated under reduced pressure and loaded to a silica gel column. The column 
was eluted using DCM and methanol solvent mixture with the proportion from (100:0) to 
(95:5) to afford 19 and 22. 
Hydrolysis of hexaazidoneomycin B  
To 25 mL of methanol cooled to 0 °C, 12.5 mL of acetyl chloride (excess) was 
added dropwise, keeping the flask in the ice bath and stirred for 5 minutes. Then, 0.5 g 
hexaazidoneomycin B 60 (0.64mmol, 1 equivalent) was added to the reaction mixture. 
After 48 hours of the reaction at room temperature, the formation of the product was 
confirmed by TLC (DCM: Methanol = 90:10, Rf = 0.8). The crude reaction mixture was 
concentrated under reduced pressure and loaded to a silica gel column. The column was 
eluted using DCM and methanol solvent mixture with the proportion from (100:0) to 











Hydrolysis of tetraazidokanamycin A  
To 25 mL of acetonitrile cooled to 0 °C, 0.33 mL of TMSOTf (1.87 mmol, 2.2 
equivalent) was added dropwise, keeping the flask in the ice bath and stirred for 5 
minutes. Then, 0.5 g of azidokanamycin (0.85mmol, 1 equivalent) was added to the 
reaction mixture.  After 48 hours of the reaction at room temperature, the formation of 
the product was confirmed by TLC (DCM: Methanol = 90:10, Rf = 0.4 to 0.8). The 
reaction solution was quenched with methanol, concentrated under reduced pressure, and 
the crude reaction mixture was loaded to a silica gel column. The column was eluted 
using DCM and methanol solvent mixture with the proportion from (100:0) to (95:5) to 
afford 18. 
Hydrolysis of pentaazidokanamycin B 
To 25 mL of acetonitrile cooled to 0 °C, 0.33 mL of TMSOTf (1.87 mmol, 2.2 
equivalent) was added dropwise, keeping the flask in the ice bath and stirred for 5 
minutes. Then 0.5g of pentaazdiokanamycin B (0.81mmol, 1 equivalent) was added to 
the reaction mixture. After 48 hours of the reaction at room temperature, the formation of 
the product was confirmed by TLC (DCM: Methanol = 90:10, Rf = 0.6 to 0.8). The 
reaction solution was quenched with methanol, concentrated under reduced pressure, and 
the crude reaction mixture was loaded to a silica gel column. The column was eluted 
using DCM and methanol solvent mixture with the proportion from (100:0) to (95:5) to 







Hydrolysis of hexaazidoneomycin B 
To 25 mL of acetonitrile cooled to 0 °C, 0.5 mL of TMSOTf (2.816 mmol, 4.4 
equivalent) was added dropwise, keeping the flask in the ice bath and stirred for 5 
minutes. Then 0.5g of hexaazidoneomycin B (0.64mmol, 1 equivalent) was added to the 
reaction mixture.  After 48 hours of the reaction at room temperature, the formation of 
the product was confirmed by TLC (DCM: Methanol = 90:10, Rf = 0.8). The reaction 
solution was quenched with methanol, concentrated under reduced pressure, and the 
crude reaction mixture was loaded to silica gel column. The column was eluted using 
DCM and methanol solvent mixture with the proportion from (100:0) to (95:5) to afford 
22. 
2-2.2 Hydrolysis of Tetrakis (bezyloxycarbonyl) kanamycin A (Z4K) in methanol, 
isopropanol, and octanol  
  
Z4K in methanol 
To 25 mL of methanol cooled to 0 °C, 8.33 mL of acetyl chloride (excess) was 
added dropwise, keeping the flask in the ice bath and stirred for 5 minutes. Then 1.0 g of 
Z4K (0.97 mmol, 1 equivalent) was added to the reaction mixture. After refluxing the 
reaction mixture for 12 hours, the formation of the product was confirmed by TLC 
(DCM: Methanol = 90:10, Rf = 0.1 to 0.4). The crude reaction mixture after concentrated 
under reduced pressure and loaded to a silica gel column. The column was eluted using 








Z4K in isopropanol 
To a solution of 1 g of Z4K (0.97 mmol, 1 equivalent) in 10 mL of anhydrous 
dioxane, 10 mL of anhydrous dioxane-HCl (4M) was added, followed by the addition of 
isopropanol (11.76 mmol, 12 equivalent) and stirred for 5 minutes. After refluxing the 
reaction mixture for 12 hours, the formation of the product was confirmed by TLC 
(DCM: Methanol = 90:10, Rf = 0.1 to 0.6). The crude reaction mixture after concentrated 
under reduced pressure and loaded to a silica gel column. The column was eluted using 
DCM and methanol solvent mixture with the proportion from (100:0) to (95:5) to afford 
26 and 30-32. 
Z4K in octanol 
To a solution of 1 gram of Z4K (0.97 mmol, 1 equivalent) in 10 mL of anhydrous 
dioxane, 10 mL of anhydrous dioxane-HCl (4M) was added followed by the addition of 
1-octanol (11.76 mmol, 12 equivalent) and stirred for 5 minutes. After refluxing the 
reaction mixture for 12 hours, the formation of the product was confirmed by TLC 
(DCM: Methanol = 90:10, Rf = 0.1 to 0.7). The crude reaction mixture after concentrated 
under reduced pressure and loaded to a silica gel column. The column was eluted using 
DCM and methanol solvent mixture with the proportion from (100:0) to (97:3) to afford 
26 and 32-34.   
2-2.3 General procedure for acetylation 
To a solution (0.1 g, 0.305 mmol) of glucopyranose in acetic anhydride at 0oC, 6-7 drops 
of concentrated H2SO4 were added slowly and stirred overnight at room temperature. The 
saturated NaHCO3 (aq) and ethyl acetate (50 mL) were added to the reaction mixture 
after the confirmation of reaction completion by TLC (Hexane: Ethyl acetate= 50:50, Rf = 
17 
 
0.7 for 28 and 0.4 for 29). After stirring for an hour, the organic layer was separated, 
washed with water and brine, and dried over Na2SO4. The products (28-29) obtained 






3-1 Synthesis of 3- and 6- aminosugar via the new route 
Various solvents and acids were examined for the hydrolysis of 
tetraazidokanamycin A and these results are summarized the results in Table 3-1. For 
purification, all the reactions were quenched with methanol to yield methyl glycosides 
except when using methanol as a solvent (Entry 1). From the results, HCl generated from 
mixing AcCl with MeOH provided the best outcome to obtain 3- and 6-aminosugar 
precursors, yielding compounds 18 (34%), 19 (11%), and 20 (2%). The isolated 
azidosugars, 19 and 20, can be converted into the corresponding glycosyl donors using 
reported protocol.61 All other conditions generated either no hydrolysis or a mixture of 
products that could not be separated. The reason might be an issue of the solubility of the 
starting material in the solvent used or the acid not being strong enough to hydrolyze the 
glycosidic bond.  
With the establishment of optimal conditions, we also examined the acid-
catalyzed hydrolysis using pentaazidokanamycin B (21) and hexaazidoneomycin B (23) 
(scheme 3-1). Two conditions were examined: AcCl/MeOH and TMSOTf/MeCN. 
Interestingly, for pentaazidokanamycin B, only the glycosidic bond between rings II and 
III was cleaved, resulting in the formation of tetraazidoneamine and the corresponding 3-
azidosugar (ring III). For the hydrolysis of hexaazidoneomycin B, there was also no 
hydrolysis of the glycosidic bond between rings I and II, leading to the formation of 
tetraazidoneamine and a mixture probably produced from breaking of the glycosidic 
bonds between rings II and III and between rings III and IV. Hydrolysis of 
19 
 
azidokanamycin A, which has a hydroxyl group (-OH) at a 2′ position, resulted in the 
breaking of the glycosidic bond between ring I and II. The presence of the hydroxyl 
group could have eased the intramolecular hydrogen bonding to favor the hydrolysis of 
the glycosidic bond. However, the absence of intramolecular hydrogen bonding in the 
presence of the azido group (N3) in 21 and 23 could have prohibited the breaking of the 
bond between ring I and II in the aminoglycosides subjected to hydrolysis. This result is 
consistent with the hydrolysis of azidotobramycin that has been reported previously.58 
 
 
Table 3-1. Hydrolysis of tetraazidokanamycin A 
 
 
Entry Solvents Acid Product (% yield) 
1 MeOH HCl (MeOH and AcCl) 18 (34) + 19 (11) +20 (2) 
2 DCM TMSOTf No Hydrolysis 
3 DCM BF3-OEt2 No Hydrolysis 
4 1,4-dioxane TMSOTf 18 (90) +inseparable mixture 
5 Acetonitrile TMSOTf 













Although acid-catalyzed hydrolysis of tetraazidokanamycin A furnished desired 
aminosugars, the cost of synthesis was high and the yield poor. Therefore, we also 
examined the use of tetracarbobenzoxy (Cbz)-protected kanamycin A 24 62 to provide 
aminosugars. The synthesis of 24 from kanamycin A was much cheaper, resulting in a 
higher yield and involving no safety issues compared to the synthesis of azidokanamycin 
A. Compound 24 was subjected to hydrolysis using MeOH/AcCl and various Lewis 
acids. To our delight, not only could the Cbz-protected aminosugars be obtained by using 
MeOH/AcCl (Method 1), but the yields were better than with hydrolysis of 
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tetraazidokanamycin A (Scheme 3-2). The subsequent acetylation of compound 25 and 
27 resulted in the synthesis of amino sugar donor precursors, compounds 28 and 29, in 
excellent yield. Interestingly, there was no hydrolysis when using other acids like TsOH, 
TMSOTf, and BF3-OEt2.  
 




3-2 One-pot glycosylation 
Glycosylation is a natural enzymatic process catalyzed by glycosyltransferases. 
However, it is somewhat unusual in chemical synthesis. To expand the applications of the 
developed protocol, we attempted to explore the possibility of utilizing alcohols other 
than methanol for the hydrolysis so that the methodology can be feasible for possible 
chemical glycosylation. In this design, the aminosugars on aminoglycosides will undergo 
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cleavage of glycosidic bonds and subsequent glycosylation with provided alcohol in one-
pot. Among the alcohols and acids examined, both isopropanol and 1-octanol under 4 N 
HCl in 1,4-dioxane produced the hydrolyzed adducts (Scheme 3-3). Although only 
modest yields were obtained, the outcome proved that it is possible to conduct hydrolysis 
of 24 and use the hydrolyzed aminosugars for chemical glycosylation. 










3-3 Characterization of 1H-NMR and 13C-NMR 
 
 
1,3-diazido-2-deoxystreptamine (18) 60 
Yield: 34%; white solid; 1H NMR (CD3OD, 500 MHz): δ 3.38 (m, 2H), 3.18 - 
3.27 (m, 3H), 2.09 (dt, J = 4.4 Hz, 1H), 1.25 (q, J = 12.6 Hz, 1H). 
 
 
Methyl 3-Azido-3-deoxy-D-glucopyranoside (19) 61 
Yield: 11%; light white oil (α: β anomers = 3:2); α anomer: 1H NMR (CD3OD, 
500 MHz): δ 4.85 (d, J = 3.6 Hz, 1H), 3.91 (dd, J = 2.1, 12.2 Hz, 1H), 3.83 - 3.47 (m, 
5H), 3.62 (s, 3H). 
 
 
Methyl 6-Azido-6-deoxy-D-glucopyranoside (20)63 
Yield: 2%; light white oil (α: β anomers = 1:1); α anomer: 1H NMR (CD3OD, 500 
MHz): δ 4.70 (d, J = 3.6 Hz, 1H), 3.61 (dd, J = 2.1, 12.2 Hz, 1H), 3.54 -3.37 (m, 4H), 





 1,3,2′,6′-Tetraazidoneamine (22)64 
Yield: 90%; white solid; 1H NMR (CD3OD, 500 MHz): δ 5.63 (d, J = 3.7 Hz, 
1H), 4.16 (ddd, J = 10.4, 5.6, 2.8 Hz, 1H), 3.85 (dd, J = 10.4, 8.7 Hz, 1H), 3.55 - 3.33 (m, 
6H), 3.31 - 3.21 (m, 2H), 3.12 (dd, J = 10.5, 3.8 Hz, 1H), 2.24 (dt, J = 13.1, 4.2 Hz, 1H), 
1.89 (q, J = 12.5 Hz, 1H).  
 
 
Methyl 6-Benzyloxycarbonylamino-6-deoxy-D-glucopyranoside (25)65 
Yield: 50%; white solid (α: β anomers = 2:1); α anomer: 1H NMR (DMSO-d6, 
500 MHz) δ 7.65 – 7.09 (m, 5H), 5.10 (s, 2H), 4.65 (d, J = 3.8 Hz, 1H), 3.61 – 3.56 (m, 
1H), 3.56 – 3.54 (m, 4H), 3.54 (d, J = 2.9 Hz, 1H), 3.49 (s, 1H), 3.39 (dd, J = 9.6, 3.8 Hz, 




Yield: 62%; white solid; 1H NMR (DMSO-d6, 500 MHz) δ 7.46 – 7.32 (m, 10H), 
7.31 (d, J = 6.7 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 5.00 (q, J = 12.7 Hz, 4H), 4.88 (s, 1H), 
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4.71 (s, 1H), 4.13 (s, 1H), 3.24 (d, J = 8.9 Hz, 2H), 3.09 – 2.97 (m, 3H), 1.81 (d, J = 12.0 
Hz, 1H), 1.26 – 1.16 (m, 1H). 
 
 
Methyl 3-Benzyloxycarbonylamino-3-deoxy-D-glucopyranoside (27) 
Yield: 75%; white solid; α anomer: 1H NMR (CD3OD, 500 MHz) δ 7.54 – 7.16 
(m, 5H), 5.11 (s, 2H), 4.71 (d, J = 3.6 Hz, 1H), 3.87 – 3.75 (m, 2H), 3.69 (dd, J = 11.8, 
5.5 Hz, 1H), 3.64 – 3.56 (m, 1H), 3.50 (dd, J = 11.1, 2.5 Hz, 1H), 3.46 (s, 3H), 3.37 (t, J 
= 9.8 Hz, 1H); 13C NMR (CD3OD, 500 MHz) δ 158.27, 136.99, 128.02(3C), 127.48(2C), 
99.46, 72.69, 70.33, 68.61, 66.08, 61.29, 56.59, 54.10; ESI/APCI calculated for 




Acetyl 3-Benzyloxycarbonylamino-2,4,6-tri-O-actyl-3-deoxy-D-glucopyranoside (29) 67 
Yield: 85%; yellowish oil; α anomer: 1H NMR (CDCl3, 500 MHz)  δ 7.43 – 7.27 
(m, 5H), 6.35 (d, J = 3.8 Hz, 1H), 5.49 (t, J = 9.8 Hz, 1H), 5.22 – 5.08 (m, 3H), 4.33 – 
4.27 (m, 1H), 4.27 – 4.20 (m, 2H), 4.15 (dd, J = 8.5, 5.3 Hz, 1H), 2.36 – 1.78 (m, 12H); 
13C NMR (CDCl3, 500 MHz) δ 170.64, 169.65, 169.39, 168.75, 167.75, 132.45, 130.87, 
128.80, 128.57, 128.25, 89.07, 69.89, 69.83, 69.19, 68.16, 67.89, 66.32, 61.46, 20.88, 




Acetyl 6-Benzyloxycarbonylamino-2,3,4-tri-O-actyl-6-deoxy-D-glucopyranoside (28) 67 
Yield: 87%; yellowish oil; α anomer: 1H NMR (CDCl3, 500 MHz) δ 7.47 – 7.13 
(m, 5H), 6.32 (d, J = 3.7 Hz, 1H), 5.57 – 5.46 (m, 1H), 5.26 – 5.19 (m, 1H), 5.19 – 5.07 
(m, 2H), 4.34 (dd, J = 12.7, 3.8 Hz, 1H), 4.31 – 4.23 (m, 1H), 4.04 – 3.84 (m, 1H), 3.32 – 
3.15 (m, 1H), 2.13 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H); 13C NMR (CDCl3, 500 
MHz) δ 170.31, 170.14, 169.77, 168.99, 167.75, 132.43, 130.87, 128.78 (3C), 88.97, 
70.57, 69.68, 69.36, 68.67, 68.14, 53.43, 20.87, 20.65, 20.63, 20.44. 
 
Isopropyl 6-Benzyloxycarbonylamino-6-deoxy-D-glucopyranoside (30) 
Yield: 9%; white solid (α: β anomers = 1:1); β anomer: 1H NMR (CD3OD, 500 
MHz) δ 7.48 – 7.28 (m, 5H), 5.10 (d, J = 4.1 Hz, 2H), 4.31 (d, J = 7.6 Hz, 1H), 3.93 – 
3.85 (m, 1H), 3.68 (ddd, J = 11.6, 7.3, 3.7 Hz, 1H), 3.59 (ddd, J = 16.5, 13.3, 7.5 Hz, 
3H), 3.18 – 3.10 (m, 2H), 1.24 – 1.14 (m, 6H); 13C NMR (CD3OD, 500 MHz) δ 157.76, 
135.40, 128.08 (2C), 127.47 (3C), 101.34, 76.34, 74.53, 72.09 , 70.57, 69.71, 66.05 , 





Isopropyl 3-Benzyloxycarbonylamino-3-deoxy-α-D-glucopyranoside (31) 
Yield: 32%; white solid; α anomer: 1H NMR (CD3OD, 500 MHz) δ 7.42 – 7.27 
(m, 5H), 5.11 (s, 2H), 4.92 (d, J = 3.7 Hz, 1H), 4.00 (dt, J = 12.3, 6.2 Hz, 1H), 3.79 (t, J = 
10.0 Hz, 2H), 3.75 – 3.65 (m, 2H), 3.45 (dd, J = 10.6, 3.6 Hz, 1H), 3.39 – 3.34 (m, 1H), 
1.29 (d, J = 6.2 Hz, 3H), 1.22 (t, J = 8.2 Hz, 3H); 13C NMR (CD3OD, 500 MHz) δ 
157.72, 137.01, 127.98 (2C), 127.46 (3C), 96.42, 72.76, 70.29, 69.56, 68.80, 66.05, 
61.31, 56.55, 22.27, 20.23. 
 
 
Isopropyl 3-Benzyloxycarbonylamino-3-deoxy-D-glucopyranoside (32) 
Yield: 42%; white solid (α: β anomers = 1:1); β anomer: 1H NMR (CD3OD, 500 
MHz) δ 7.79 – 6.87 (m, 5H), 5.20 – 5.03 (m, 2H), 4.41 (d, J = 7.8 Hz, 1H), 3.87 (dd, J = 
11.7, 1.6 Hz, 1H), 3.75 – 3.64 (m, 1H), 3.59 – 3.49 (m, 1H), 3.45 (dd, J = 10.6, 3.7 Hz, 
1H), 3.39 – 3.35 (m, 2H), 3.21 (ddd, J = 13.7, 7.0, 3.5 Hz, 1H), 1.23 (dd, J = 15.8, 6.2 
Hz, 6H) ; 13C NMR (CD3OD, 500 MHz) δ 158.26, 136.99 , 127.98 (3C) , 127.44 (2C) , 
101.85, 77.66 , 71.93 , 71.14, 68.79, 67.70, 61.36, 59.74, 22.41, 20.65. 
 
 
Octyl 6-Benzyloxycarbonylamino-6-deoxy-D-glucopyranoside (33) 
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Yield: 10%; white solid (α: β anomers = 1:1); α anomer: 1H NMR (CD3OD, 500 
MHz) δ 7.41 – 7.29 (m, 5H), 5.10 (s, 2H), 4.75 (d, J = 3.8 Hz, 1H), 3.85 (dt, J = 9.5, 6.8 
Hz, 1H), 3.68 – 3.57 (m, 3H), 3.46 – 3.35 (m, 2H), 3.21 – 3.12 (m, 2H), 1.67 – 1.55 (m, 
2H), 1.36 – 1.27 (m, 10H), 0.91 (t, J = 6.9 Hz, 3H); 13C NMR (CD3OD, 500 MHz) δ 
157.72 , 136.98, 128.15 (3C), 127.39(2C), 98.56, 76.34, 74.62, 72.21, 71.68, 69.52, 
67.77, 66.49,  31.45, 29.43, 29.34, 25.91, 25.72, 22.32, 13.05; ESI/APCI calculated for 
C22H35NO7Na ([M + Na]+ ) m/z 448.2311, measured m/z 448.2314. 
 
 
Octyl 3-Benzyloxycarbonylamino-3-deoxy-D-glucopyranoside (34) 
Yield: 18%; white solid (α: β anomers = 4:1); α anomer: 1H NMR (CD3OD, 500 
MHz) δ 7.66 – 7.02 (m, 5H), 5.11 (s, 2H), 4.80 (d, J = 3.6 Hz, 1H), 3.96 – 3.85 (m, 1H), 
3.84 – 3.74 (m, 2H), 3.73 – 3.58 (m, 2H), 3.60 – 3.45 (m, 2H), 3.36 (d, J = 9.9 Hz, 1H), 
1.76 – 1.51 (m, 2H), 1.48 – 1.27 (m, 10H), 0.92 (td, J = 6.8, 2.3 Hz, 3H);  13C NMR 
(CD3OD, 500 MHz) δ 158.33 , 136.97, 128.01(3C), 127.46(2C), 98.29 , 77.67, 71.92, 
70.42, 69.48, 68.71, 67.77 , 66.10, 61.34, 56.63, 31.64, 29.04, 25.74, 22.35, 13.07; 









CONCLUSIONS AND SIGNIFICANCE 
Our laboratory has previously synthesized TC007 and identified it as a potent lead 
in the treatment of spinal muscular atrophy. By modifying the old route, the synthetic 
steps were shortened, and yield increased.  
The acid-catalyzed hydrolysis of tetraaazidokanamycin A, pentaazidokanamycin 
B, and Z4K were analyzed. The synthesis of 3- and 6- amino sugars from the hydrolysis 
of tetraazidokanamycin A was a turning point in shortening the synthetic steps involved. 
The cost of amino sugar preparation was low; however, the yields were 11% for 3- 
aminosugar and 2% for 6- aminosugar. Utilizing the same established protocol, 
hydrolysis of pentaazidokanamycin B resulted 90% yield of 3-amino sugar. The cost of 
azidokanamycin B, being 25 times more, could not override the shortcomings of utilizing 
azidokanamycin A in the hydrolysis. Last but not the least, we synthesized, z4k, a very 
cheap starting material compared to azidokanamycin A and B. The production of 3- and 
6- amino sugars from the hydrolysis of z4k were in excellent yield compared to the 
hydrolysis of tetraazidokanamycin A and was cost-effective compared to both 
azidokanamycin A and B.  Finally, we have developed convenient protocols to furnish 
the protected 3- and 6-aminosugars. These protocols utilizing the hydrolysis of 
aminoglycosides are cost-effective, result in higher yields, and can shorten the synthetic 
steps as compared to other methods using unmodified pyranoses as the starting material.  
In addition, our results from the hydrolysis of different aminoglycosides suggest 
that the presence of hydrogen bonding at a 2′ position can direct the composition of 
products from acid hydrolysis of aminoglycosides.  
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